STAT+: UnitedHealth CEO concedes company was ‘over-optimistic’ about Change cyberattack recovery
UnitedHealth Group’s CEO said Tuesday that his team was “over-optimistic” about the pace at which…
Category: STAT+
STAT+: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: A cancer care startup is making a new bet with payers and providers: only pay if it works
A cancer care navigation startup has raised $95 million from prominent tech investors to help…
STAT+: Medicare pay proposals are good news for health tech, bad news for docs
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Early data from Lexeo’s gene therapy for rare heart disease shows promise
Lexeo Therapeutics said Monday that a gene therapy designed to prevent fatal cardiac complications of…
STAT+: The effort to reform physician pay is set to pit primary care docs against highly paid specialists
WASHINGTON — There’s been a long lull in fighting between primary care and specialty doctors…
STAT+: Top FDA officials weighing regulation of ultra-processed foods, internal documents show
WASHINGTON – Top Food and Drug Administration officials met multiple times earlier this year to…
STAT+: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: The biggest misconception about CTE, according to a leading brain trauma expert
This week, the late National Hockey League veteran Greg Johnson was diagnosed with chronic traumatic…
STAT+: Medicare proposes to cover some digital therapies in a breakthrough for health tech firms
In what could prove to be a lifeline for a new crop of health tech…
STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pfizer says it will advance once-daily GLP-1 pill after all
Pfizer said that it plans to advance a new once-a-day formulation of its experimental obesity…
STAT+: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Novo Nordisk’s weekly insulin rejected by FDA
The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes…
STAT+: FTC plans to sue PBMs over the high cost of insulin and other medicines, reports say
The U.S. Federal Trade Commission reportedly plans to sue the three largest pharmacy benefit managers…
STAT+: Biden administration ignores calls to bolster hospital price transparency
The federal government will not modify regulations that dictate how hospitals publish their prices for…
STAT+: Sanford Health aims to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system
Fourth time’s the charm? Sanford Health is hoping so. Less than a year after scrapping…
Researchers identify ‘molecular switch’ in lupus that could stymie harmful immune response
Lupus, in superhero terms, tells a devastating story. A loyal hero turns villain and works…
STAT+: Pharmalittle: We’re reading about biopharma layoffs, Purdue bankruptcy talks, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: VC Flagship Pioneering raises $3.6 billion in new funds
Flagship Pioneering, one of the largest firms investing in and creating new biotech companies, said…
STAT+: Biopharma layoffs are leaving the industry’s scientists reeling — and in search of scarce opportunities
After getting laid off from Bristol Myers Squibb last December, Jennifer Ariazi is trying her…
STAT+: The pharmaceutical industry keeps losing Washington friends
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down
Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael…
STAT+: Pharmalittle: We’re reading about an FTC report on PBMs, Lilly vs. Novo weight loss study, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: FTC report finds PBMs profit at the expense of patients and independent pharmacies
In stark terms, the Federal Trade Commission found in a report released Tuesday that pharmacy…
Opinion: STAT+: Private equity and neuroscience: a novel approach to developing new treatments for neurological disorders
Neurological diseases are now the leading cause of poor health and disability worldwide. An estimated…
STAT+: Drugmakers are losing crucial friends on Capitol Hill
WASHINGTON — Sen. Bob Menendez is the poster child for a pharmaceutical industry ally. He…
STAT+: A faster, simpler, cheaper cancer cell therapy is about to be tested in humans
In a long-awaited study, patients in Australia will soon receive an IV infusion designed to…
STAT+: South Africa and J&J reach a deal to widen access to a key tuberculosis treatment
South African antitrust authorities ended an investigation into Johnson & Johnson and its Janssen subsidiary…
STAT+: Pulling back the curtain on psychiatric hospital joint ventures
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: AI leads the way as health tech funding inches toward a post-pandemic stability
Funding for health tech startups in the first half of 2024 remained far below the…
STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
.jpg)
STAT+: Eli Lilly to acquire Morphic for $3.2 billion
Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for…
STAT+: Troubled for-profit chains are stealthily operating dozens of psychiatric hospitals under nonprofits’ names
Come quickly, the Columbus Police sergeant urged, patients are in danger. The psychiatric hospital on…
STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors
WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 million last year to…
STAT+: Judge rules against Boehringer Ingelheim in pharma’s latest legal loss on Medicare negotiation
WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug…
STAT+: U.K. trade group scolds Novo, Novartis, Pfizer and Otsuka for violating industry codes
Four large drugmakers — Novartis, Pfizer, Novo Nordisk, and Otsuka Pharmaceutical — were scolded by…
STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Top Biden administration officials withdraw from Coalition for Health AI
Top Biden administration officials have withdrawn from an industry body formed to set safety standards…
STAT+: Regulating artificial intelligence doesn’t have to be complicated, some experts say
Artificial intelligence has the potential to revolutionize how drugs are discovered and change how hospitals…
STAT+: New Medicare Advantage star ratings give extra bonuses to multiple insurers
More than two dozen Medicare Advantage insurers received higher quality marks for 2024, based on…
STAT+: Pharmalittle: We’re reading about a GSK vaccine deal, an Alzheimer’s drug approval, and more
Top of the morning to you, and a fine one it is. The skies are…
STAT+: What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: FDA approves Eli Lilly’s early Alzheimer’s treatment
Eli Lilly’s early Alzhiemer’s treatment was approved by the Food and Drug Administration on Tuesday,…
STAT+: Former Mass General president Peter Slavin will run Cedars-Sinai in Los Angeles
Peter Slavin, who ran Massachusetts General Hospital in Boston for nearly two decades before stepping…
STAT+: Report shows U.S. biotechs are wary of Chinese partnerships due to looming BIOSECURE Act
A looming anti-China biotechnology bill has spooked U.S. life sciences companies, according to a new…
STAT+: Pharmalittle: We’re reading about FTC probing Teva patents, a Moderna flu vaccine contract, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes
The unilateral decision by Peter Marks, a top official at the Food and Drug Administration,…
STAT+: The biotech scorecard for the third quarter: 19 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…